Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy
Authors:
- Antoine MagnanAMAntoine Magnan
- 1 June 2009
- journal article
- review article
- Published by Elsevier in Respiratory Medicine
- Vol. 103 (6) , 800-812
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Induction of FOXP3 expression in naive human CD4+FOXP3− T cells by T-cell receptor stimulation is transforming growth factor-β–dependent but does not confer a regulatory phenotypeBlood, 2007
- Safety of a SQ‐standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo‐controlled trialAllergy, 2006
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trialJournal of Allergy and Clinical Immunology, 2001
- Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma—a placebo controlled studyAnnals of Allergy, Asthma & Immunology, 1999
- Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) studyClinical & Experimental Allergy, 1996
- Immunotherapy with a standardized Dermatophagoides pteronyssinus extractJournal of Allergy and Clinical Immunology, 1989
- Does the effect of immunotherapy last after termination of treatment?Allergy, 1988
- Generation of Antigen-Specific Suppressor Cells during Allergy DesensitizationNew England Journal of Medicine, 1980
- In Vitro Studies of Human Ragweed Allergy: Changes in Cellular and Humoral Activity Associated with Specific Desensitization*Journal of Clinical Investigation, 1966